J Endocrinol Metab
Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc
Journal website http://www.jofem.org

Editorial

Volume 7, Number 5, October 2017, pages 133-134


Major Component Diseases, Autoantibodies, and Typical Clinical and Endocrinological Findings Observed in Each Type of Polyglandular Autoimmune Syndrome

Hidekatsu Yanai

Department of Internal Medicine, National Center for Global Health and Medicine, Kohnodai Hospital, 1-7-1 Kohnodai, Ichikawa, Chiba 272-8516, Japan

Manuscript submitted September 22, 2017, accepted October 4, 2017
Short title: Polyglandular Autoimmune Syndrome
doi: https://doi.org/10.14740/jem452w

In this issue (P159), Oleo et al report a patient with polyglandular autoimmune syndrome (PAS) 3B [1], and they concluded that it is important to monitor for the development of new autoimmune diseases in patients with PAS. I completely agree with their conclusion.

To detect the newly onset of autoimmune diseases, we should have sufficient knowledge about PAS. We previously reported clinical, endocrinological and immunological characteristics of Japanese patients with PAS3A [2]. The relationship of immunological phenotype with clinical and endocrinological phenotypes is very complicated. In type 1 diabetic patients with PAS3A, approximately 80% of patients showed the positivity for anti-glutamic acid decarboxylase antibody; however, intrinsic insulin secretion has been preserved in almost half of PAS3A patients. Furthermore, although the positivity for anti-thyroid peroxidase antibody was observed in about 70% of PAS3A patients, only 15% of PAS3A patients showed hypothyroidism or thyroid swelling. To predict the development of new autoimmune disease, we should be familiar with autoantibodies and clinical manifestation of each type of PAS.

Major component diseases, autoantibodies, and typical clinical and endocrinological findings observed in each type of PAS which was made by modification of previous reports are shown in Table 1 [3-5]. In addition to the information in Table 1, I would like to mention that the measurement of autoantibody to interferon-ω is useful to detect PAS type 1 [6, 7].

Table 1.
Click to view
Table 1. Major Component Diseases, Autoantibodies, and Typical Clinical and Endocrinological Findings Observed in Each Type of Polyglandular Autoimmune Syndrome (PAS)
 

I really hope that this editorial will help physicians and scientists to elucidate the pathophysiology and treatment for PAS.

Competing Interests

The author declares that he has no competing interests concerning this article.


References▴Top 
  1. Oleo IERD, Saldarriaga MM, Silverman M, Thibaud S, Sponholz LR. Polyglandular autoimmune syndrome Type 3B: hyperthyroidism and pernicious anemia a reminder of the past. J Endocrinol Metab. 2017;7(5):159-161.
    doi
  2. Moriyama S, Yoshikawa R, Katsuyama H, Hamasaki H, Adachi H, Yanai H. Clinical, endocrinological and immunological characteristics of Japanese patients with autoimmune polyglandular syndrome type 3a. J Endocrinol Metab. 2016;6(2):46-51.
    doi
  3. Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev. 2002;23(3):327-364.
    doi pubmed
  4. Hamasaki H, Yanai H, Hiraishi C, Moriyama S. A significant discrepancy between endocrinological and clinical phenotype and immunological phenotype in autoimmune polyglandular syndrome type 3. J Med Cases. 2012;3(1):1-3.
    doi
  5. Takazono T, Izumikawa K, Nagayoshi Y, Tanaka A, Mihara T, Kosai K, Saijo T, et al. Evaluation of the Cica Fungi Test Candida, a novel serum Candida mannan antigen kit, and its comparison with Cand-Tec in candidemia patients. Jpn J Infect Dis. 2011;64(2):116-120.
    pubmed
  6. Larosa MDP, Mackenzie R, Burne P, Garelli S, Barollo S, Masiero S, Rubin B, et al. Assessment of autoantibodies to interferon-omega in patients with autoimmune polyendocrine syndrome type 1: using a new immunoprecipitation assay. Clin Chem Lab Med. 2017;55(7):1003-1012.
    doi pubmed
  7. Bruserud O, Oftedal BE, Landegren N, Erichsen MM, Bratland E, Lima K, Jorgensen AP, et al. A Longitudinal Follow-up of Autoimmune Polyendocrine Syndrome Type 1. J Clin Endocrinol Metab. 2016;101(8):2975-2983.
    doi pubmed


This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Journal of Endocrinology and Metabolism is published by Elmer Press Inc.

 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

DECLARATION: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!